In a report released today, Raj Denhoy from Jefferies reiterated a Hold rating on Boston Scientific Corp (NYSE: BSX), with a price target of $28. The company’s shares opened today at $26.45, close to its 52-week high of $26.76.
According to TipRanks.com, Denhoy is a top 100 analyst with an average return of 15.3% and a 70.4% success rate. Denhoy covers the Healthcare sector, focusing on stocks such as Varian Medical Systems, Zimmer Biomet Holdings, and Edwards Lifesciences.
Currently, the analyst consensus on Boston Scientific Corp is Moderate Buy and the average price target is $28.25, representing a 6.8% upside.
In a report released today, Goldman Sachs also initiated coverage with a Hold rating on the stock with a $28 price target.
The company has a one year high of $26.76 and a one year low of $19.67. Currently, Boston Scientific Corp has an average volume of 7.41M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. Its products and technologies are used to diagnose or treat medical conditions, including heart, digestive, pulmonary, vascular, urological, women’s health and chronic pain conditions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.